Lyra Therapeutics Inc (LYRA) concluded trading on Wednesday at a closing price of $0.10, with 27.13 million shares of worth about $2.71 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -59.44% during that period and on May 07, 2025 the price saw a gain of about 2.94%. Currently the company’s common shares owned by public are about 65.88M shares, out of which, 54.86M shares are available for trading.
Stock saw a price change of -11.62% in past 5 days and over the past one month there was a price change of -6.17%. Year-to-date (YTD), LYRA shares are showing a performance of -49.13% which decreased to -97.39% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.08 but also hit the highest price of $0.49 during that period. The average intraday trading volume for Lyra Therapeutics Inc shares is 1.40 million. The stock is currently trading 4.88% above its 20-day simple moving average (SMA20), while that difference is down -23.42% for SMA50 and it goes to -50.87% lower than SMA200.
Lyra Therapeutics Inc (NASDAQ: LYRA) currently have 65.88M outstanding shares and institutions hold larger chunk of about 37.77% of that.
The stock has a current market capitalization of $6.92M and its 3Y-monthly beta is at 0.05. It has posted earnings per share of -$1.21 in the same period. It has Quick Ratio of 3.41 while making debt-to-equity ratio of 8.62. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LYRA, volatility over the week remained 14.41% while standing at 16.44% over the month.
Stock’s fiscal year EPS is expected to rise by 55.94% while it is estimated to decrease by -5.45% in next year. EPS is likely to grow at an annualized rate of 21.95% for next 5-years, compared to annual growth of -2.22% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on May 07, 2024 offering a Hold rating for the stock and assigned a target price range of between $10 and $0.50 to it. Coverage by H.C. Wainwright stated Lyra Therapeutics Inc (LYRA) stock as a Neutral in their note to investors on May 07, 2024, suggesting a price target of $2 for the stock. Stock get a Buy rating from BTIG Research on October 06, 2023.
